Prostate Cancer Radioligand Therapy: Beta-labeled Radiopharmaceuticals
PET Clinics(2024)
摘要
Prostate cancer is the most common malignancy in men worldwide, with an estimated 174,650 new cases per year in the United States, and the second cancer-related cause of death, after lung cancer, with 31,620 deaths per year. While the 5 year survival rate for prostate cancer in patients without metastatic spread is nearly 100%, those with distant metastases have 5 year survival rates of approximately 30%. Initial diagnosis and assessment are based on PSA levels, Gleason score (derived from prostate biopsy), and advanced imaging modalities, including prostate MR imaging and PSMA-PET/computed tomography in patients with high-risk features.
更多查看译文
关键词
Prostate cancer,mCRPC,PSMA-PET/CT,FDG-PET/CT,Lu-177 PSMA,PSMA-based radioligand therapy,Dosimetry
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要